Back

Eligibility for semaglutide according to the SELECT trial in a Portuguese cohort of acute coronary syndrome

13 May 2024 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention Obesity HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vanessa Lopes

Centro Hospitalar E Universitario De Coimbra, Coimbra (Portugal)

5 More presentations in this session

Presentation thumbnail
Evaluation of the triglyceride-glucose index as a predictor of metabolic syndrome in elderly population. EVITGA-60 study
Doctor L. Calvo Betancourt (Bogota, CO)
Abstract Slides Video
Presentation thumbnail
Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i
Doctor V. Medovchshikov (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Prevalence and incidence of heart failure in patients with type 2 diabetes mellitus. Results of the prospective DIABET-IC study
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
CTO recanalization in type 2 diabetic patients: procedural and long-term prognosis
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on exercise-induced hypertrophy: insights from a rodent model of athlete's heart
Doctor A. Olah (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention

The Event

Event poster

Heart Failure 2024

13 May 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Prevalence of SELECT-eligibility and incidence of 5-year major adverse cardiovascular outcomes in non-diabetic patients with myocardial infarction
thumbnail
Congress Presentation
Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations
thumbnail
Congress Presentation
Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources